ANI Pharmaceuticals (NASDAQ:ANIP) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

60.7% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 13.6% of Galectin Therapeutics shares are held by institutional investors. 33.1% of ANI Pharmaceuticals shares are held by company insiders. Comparatively, 45.2% of Galectin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

ANI Pharmaceuticals has a beta of 2.74, suggesting that its stock price is 174% more volatile than the S&P 500. Comparatively, Galectin Therapeutics has a beta of 2.66, suggesting that its stock price is 166% more volatile than the S&P 500.

Earnings and Valuation

This table compares ANI Pharmaceuticals and Galectin Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ANI Pharmaceuticals $176.84 million 3.57 -$1.07 million $3.61 14.77
Galectin Therapeutics N/A N/A -$16.23 million ($0.49) -12.47

ANI Pharmaceuticals has higher revenue and earnings than Galectin Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ANI Pharmaceuticals and Galectin Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ANI Pharmaceuticals 0.06% 27.76% 12.34%
Galectin Therapeutics N/A N/A -218.06%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for ANI Pharmaceuticals and Galectin Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ANI Pharmaceuticals 0 0 2 0 3.00
Galectin Therapeutics 0 0 3 0 3.00

ANI Pharmaceuticals currently has a consensus target price of $74.50, indicating a potential upside of 39.72%. Galectin Therapeutics has a consensus target price of $8.33, indicating a potential upside of 36.39%. Given ANI Pharmaceuticals’ higher probable upside, analysts clearly believe ANI Pharmaceuticals is more favorable than Galectin Therapeutics.

Summary

ANI Pharmaceuticals beats Galectin Therapeutics on 10 of the 12 factors compared between the two stocks.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for severe and chronic pain; Propafenone to treat arrhythmia; Propranolol ER, Inderal LA, and Pindolol for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.

About Galectin Therapeutics

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease, skin disease, and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.